Market Closed -
OTC Markets
18:23:54 15/05/2024 BST
|
5-day change
|
1st Jan Change
|
0.021
USD
|
+28.83%
|
|
+28.83%
|
-18.92%
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
173.3
|
4.816
|
2.634
|
5.008
|
3.783
|
2.289
|
Enterprise Value (EV)
1 |
172.5
|
4.67
|
2.636
|
5.003
|
3.887
|
2.525
|
P/E ratio
|
-131
x
|
-1.07
x
|
-0.99
x
|
-2.67
x
|
-5.77
x
|
-6.16
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-490
x
|
-5.96
x
|
-1.84
x
|
-10.4
x
|
-21.9
x
|
85.7
x
|
FCF Yield
|
-0.2%
|
-16.8%
|
-54.2%
|
-9.61%
|
-4.56%
|
1.17%
|
Price to Book
|
148
x
|
18.1
x
|
-417
x
|
-365
x
|
-32.2
x
|
-9.08
x
|
Nbr of stocks (in thousands)
|
43,881
|
53,511
|
53,984
|
55,772
|
60,522
|
64,022
|
Reference price
2 |
3.950
|
0.0900
|
0.0488
|
0.0898
|
0.0625
|
0.0358
|
Announcement Date
|
28/09/18
|
30/09/19
|
28/09/20
|
12/10/21
|
28/09/22
|
28/09/23
|
Fiscal Period: Juni |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-1.283
|
-3.933
|
-2.637
|
-1.844
|
-0.564
|
-0.2826
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-1.283
|
-4.301
|
-2.672
|
-1.86
|
-0.6264
|
-0.3619
|
Net income
1 |
-1.283
|
-4.301
|
-2.672
|
-1.86
|
-0.6264
|
-0.3619
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.0301
|
-0.0843
|
-0.0495
|
-0.0336
|
-0.0108
|
-0.005805
|
Free Cash Flow
1 |
-0.3519
|
-0.7837
|
-1.429
|
-0.4806
|
-0.1774
|
0.0295
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/09/18
|
30/09/19
|
28/09/20
|
12/10/21
|
28/09/22
|
28/09/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
0
|
-
|
0.1
|
0.24
|
Net Cash position
1 |
0.82
|
0.15
|
-
|
0.01
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-0.35
|
-0.78
|
-1.43
|
-0.48
|
-0.18
|
0.03
|
ROE (net income / shareholders' equity)
|
-147%
|
-593%
|
-2,059%
|
18,470%
|
954%
|
196%
|
ROA (Net income/ Total Assets)
|
-78.4%
|
-311%
|
-988%
|
-4,769%
|
-470%
|
-211%
|
Assets
1 |
1.637
|
1.385
|
0.2703
|
0.039
|
0.1333
|
0.1717
|
Book Value Per Share
2 |
0.0300
|
0
|
-0
|
-0
|
-0
|
-0
|
Cash Flow per Share
2 |
0.0200
|
0
|
0
|
0
|
0
|
0
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/09/18
|
30/09/19
|
28/09/20
|
12/10/21
|
28/09/22
|
28/09/23
|
|
1st Jan change
|
Capi.
|
---|
| -18.92% | 1.1M | | +31.37% | 588B | | -2.60% | 364B | | +20.83% | 326B | | +5.69% | 285B | | +14.83% | 239B | | +9.93% | 210B | | -6.95% | 200B | | +10.77% | 167B | | +0.10% | 161B |
Other Pharmaceuticals
|